X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (10) 10
hypertension - drug therapy (10) 10
telmisartan/hydrochlorothiazide (9) 9
aged (7) 7
drug therapy, combination (7) 7
hydrochlorothiazide - therapeutic use (7) 7
treatment outcome (7) 7
blood pressure (6) 6
female (6) 6
hydrochlorothiazide (6) 6
index medicus (6) 6
male (6) 6
telmisartan (6) 6
antihypertensive agents - administration & dosage (5) 5
antihypertensive agents - therapeutic use (5) 5
benzimidazoles - therapeutic use (5) 5
benzoates - therapeutic use (5) 5
blood pressure - drug effects (5) 5
efficacy (5) 5
hydrochlorothiazide - administration & dosage (5) 5
internal medicine (5) 5
drug combinations (4) 4
hydrochlorothiazide - pharmacology (4) 4
losartan (4) 4
losartan/hydrochlorothiazide (4) 4
medicine & public health (4) 4
middle aged (4) 4
monotherapy (4) 4
pharmacology & pharmacy (4) 4
pharmacology/toxicology (4) 4
pharmacotherapy (4) 4
telmisartan/hydrochlorothiazide, general (4) 4
adis drug profiles (3) 3
adult (3) 3
aged, 80 and over (3) 3
ambulatory blood-pressure (3) 3
angiotensin ii receptor blocker (3) 3
angiotensin ii type 1 receptor blockers - administration & dosage (3) 3
angiotensin ii type 1 receptor blockers - therapeutic use (3) 3
antihypertensive agents - pharmacology (3) 3
antihypertensives, general (3) 3
benzimidazoles - administration & dosage (3) 3
benzoates - administration & dosage (3) 3
cardiovascular events (3) 3
diuretics (3) 3
diuretics - therapeutic use (3) 3
double-blind (3) 3
end-point probe (3) 3
essential hypertension, treatment (3) 3
hydrochlorothiazide - adverse effects (3) 3
hypertension (3) 3
hypertension - physiopathology (3) 3
medicine, research & experimental (3) 3
moderate hypertension (3) 3
open-label (3) 3
peripheral vascular disease (3) 3
plus hydrochlorothiazide (3) 3
amlodipine - therapeutic use (2) 2
angiotensin (2) 2
angiotensin ii type 1 receptor blockers - adverse effects (2) 2
angiotensin ii type 1 receptor blockers - pharmacology (2) 2
angiotensin-converting enzyme inhibitors - therapeutic use (2) 2
antihypertensive agents - adverse effects (2) 2
benzimidazoles - pharmacokinetics (2) 2
benzimidazoles - pharmacology (2) 2
benzoates - pharmacokinetics (2) 2
benzoates - pharmacology (2) 2
blood-pressure (2) 2
cardiac & cardiovascular systems (2) 2
dose-response relationship, drug (2) 2
fixed-dose combination (2) 2
hydrochlorothiazide - pharmacokinetics (2) 2
identification (2) 2
losartan - administration & dosage (2) 2
losartan - therapeutic use (2) 2
management (2) 2
medicine, general & internal (2) 2
pharmacokinetics (2) 2
randomized controlled trials as topic (2) 2
risk (2) 2
serum uric-acid (2) 2
telmisartan plus hydrochlorothiazide (2) 2
therapy (2) 2
to-moderate hypertension (2) 2
toxicology (2) 2
uric acid (2) 2
valsartan (2) 2
120 mg (1) 1
adis drug evaluations (1) 1
adolescent (1) 1
adults (1) 1
african continental ancestry group (1) 1
aldosterone (1) 1
amlodipine - administration & dosage (1) 1
amlodipine - adverse effects (1) 1
analysis (1) 1
angiotensin 1 receptor (1) 1
angiotensin ii type 1 receptor blocker (1) 1
angiotensin ii type 2 receptor blockers (1) 1
angiotensin receptor antagonists (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of the Renin-Angiotensin-Aldosterone System, ISSN 1470-3203, 12/2015, Volume 16, Issue 4, pp. 1078 - 1084
Objective: We analyzed the efficacy and safety of combination therapy of high-dose losartan (100 mg/day) and hydrochlorothiazide (HCTZ, 12.5 mg/day) compared... 
Angiotensin II type 1 receptor blocker | Blood pressure | Hydrochlorothiazide | Uric acid | Losartan | CARDIOVASCULAR EVENTS | RISK | IDENTIFICATION | angiotensin II type 1 receptor blocker | BLOOD-PRESSURE | SERUM URIC-ACID | TELMISARTAN | TELMISARTAN/HYDROCHLOROTHIAZIDE | INHIBITION | hydrochlorothiazide | DISEASE | LOSARTAN/HYDROCHLOROTHIAZIDE | PERIPHERAL VASCULAR DISEASE | losartan | uric acid | Antihypertensive Agents - pharmacology | Angiotensin II Type 1 Receptor Blockers - adverse effects | Angiotensin II Type 1 Receptor Blockers - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Antihypertensive Agents - administration & dosage | Systole - drug effects | Hypertension - drug therapy | Male | Angiotensin II Type 1 Receptor Blockers - pharmacology | Dose-Response Relationship, Drug | Hypertension - blood | Uric Acid - urine | Heart Rate - drug effects | Hydrochlorothiazide - pharmacology | Female | Blood Pressure - drug effects | Diastole - drug effects | Uric Acid - blood | Drug Therapy, Combination | Hypertension - urine | Hydrochlorothiazide - adverse effects | Losartan - pharmacology | Treatment Outcome | Hydrochlorothiazide - administration & dosage | Antihypertensive Agents - therapeutic use | Creatinine - urine | Hypertension - physiopathology | Antihypertensive Agents - adverse effects | Losartan - therapeutic use | Losartan - adverse effects | Potassium - blood | Aged | Losartan - administration & dosage | Hydrochlorothiazide - therapeutic use
Journal Article
Current Medical Research and Opinion, ISSN 0300-7995, 04/2010, Volume 26, Issue 4, pp. 879 - 887
Journal Article
Journal Article
Drugs, ISSN 0012-6667, 2008, Volume 68, Issue 13, pp. 1877 - 1899
Fixed-dose combinations of telmisartan and hydrochlorothiazide (HCTZ) [Micardis Plus®, Micardis® HCT, PritorPlus®] are available in many countries for the... 
Hypertension | Telmisartan/hydrochlorothiazide | Adis Drug Evaluations | Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | Telmisartan/hydrochlorothiazide, general | MONOTHERAPY | PHARMACOKINETICS | EFFICACY | EUROPEAN COUNTRIES | TELMISARTAN PLUS HYDROCHLOROTHIAZIDE | RECEPTOR BLOCKERS | MODERATE HYPERTENSION | PHARMACOLOGY & PHARMACY | END-POINT PROBE | OPEN-LABEL | TOXICOLOGY | AMBULATORY BLOOD-PRESSURE | Antihypertensive Agents - pharmacology | Hydrochlorothiazide - pharmacokinetics | Benzoates - therapeutic use | Area Under Curve | Benzoates - metabolism | Humans | Benzimidazoles - pharmacokinetics | Half-Life | Hypertension - drug therapy | Treatment Outcome | Antihypertensive Agents - pharmacokinetics | Antihypertensive Agents - therapeutic use | Hypertension - metabolism | Randomized Controlled Trials as Topic | Hydrochlorothiazide - metabolism | Hydrochlorothiazide - pharmacology | Benzimidazoles - metabolism | Benzoates - pharmacology | Angiotensin II Type 2 Receptor Blockers | Benzimidazoles - pharmacology | Hydrochlorothiazide - therapeutic use | Drug Combinations | Benzimidazoles - therapeutic use | Benzoates - pharmacokinetics | Type 2 diabetes | Measurement | Medical colleges | Corticosteroids | Lisinopril | Isoenzymes | Cytochrome P-450 | Aldosterone | Nifedipine | Purines | Enzyme inhibitors | Metabolites | Angiotensin | Physiological aspects | Blood pressure | Chemical properties | Drug therapy, Combination | Kidney diseases | Blood proteins | Protein binding
Journal Article
Journal Article
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.